Abivax Plunges 10.57% Amid Key Milestones

On April 24, 2025, Abivax's stock experienced a significant drop of 10.57% in pre-market trading, reflecting investor sentiment and potential market concerns.

Abivax has announced the details of its Annual General Meeting, scheduled for June 6, 2025, in Paris, France. The company is advancing toward key 2025 value-driving milestones, including the completion of enrollment for its Phase 3 ABTECT induction trials, expected in the second quarter of 2025, with top-line induction results anticipated in the third quarter of 2025.

Additionally, Abivax has appointed Dominik Höchli, MD, to its Board of Directors. Höchli brings deep immunology expertise, which is crucial as the company approaches the key Phase 3 data readout for ulcerative colitis, also expected in the third quarter of 2025. This strategic move is aimed at strengthening the company's leadership and scientific capabilities as it navigates through critical development phases.